Technology ID
TAB-3686
Radioligand for imaging brain PDE4 subtype D receptors with positron emission tomography
E-Numbers
E-107-2019-0
Lead Inventor
Pike, Victor (NIMH)
Co-Inventors
Telu, Sanjay (NIMH)
Innis, Robert (NIMH)
Nugent, Robert (Tetra Discovery Partners Inc)
Gurney, Mark (Tetra Discovery Partners Inc)
Mo, Xuesheng (Tetra Discovery Partners Inc)
Applications
Software / Apps
Research Materials
Non-Medical Devices
Medical Devices
Diagnostics
Therapeutic Areas
Psychiatry/Mental Health
Neurology
Lead IC
NIMH
ICs
NIMH
The technology relates to the first radioligands that can be used to image and quantify the enzyme phosphodiesterase subtype D (PDE4D). The PDE4D proteins have a role in carrying out signal transduction pathways in several cell types and is thought to be the key target of various antidepressants. Current work with imaging the radioligands in monkey brains using positron emission tomography (PET) has been successful, and further work with humans is needed. An effective radioligand that can visualize PDE4D levels in human using PET can be useful in evaluation of health human subjects and in the development of PDE4D inhibitors.
Commercial Applications
This radioligand can be used in the development of inhibitors of PDE4D for the treatment of depression and cognition enhancement
Competitive Advantages
There is no alternative technology for this specific purpose of PET imaging of PDE4D
Licensing Contact: